Read + Share
Rachmasari K, Montori VM. In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia
without increasing hypokalemia. Ann Intern Med 2022 Sep 6. doi: 10.7326/J22-0063.
PMID: 36063558
|
 |
|
Rachmasari K, Montori VM. In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia
without increasing hypokalemia. Ann Intern Med 2022 Sep 6. doi: 10.7326/J22-0063.
PMID: 36063558
|
|
|
|